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Background: Macular thickening (MT) without clinically recognized macular edema has been described in anterior
uveitis (AU). Although fellow-eyes of patients have been used as controls in several studies, little is known about
macular thickness in these eyes. We studied the rate and extent of MT in both AU-affected and quiescent
fellow-eyes of phakic AU patients with good visual acuity (VA). We also assessed macular thickness related to
HLA-B27 presence and to recurrence, since these issues have been almost unexplored by previous optical
coherence tomography (OCT) studies.
Methods: Patients with AU were prospectively included and macular thickness was measured with OCT initially
and on follow up. Macular thickness in patients’ affected eyes (n = 30) as well as in their quiet fellow-eyes (n = 28)
was compared with eyes of age- and gender matched controls. Inter-ocular differences in macular thickness
between AU affected eyes and their fellow-eyes were assessed in patients (n = 28), also in a subgroup with visual
acuity≥ 0.8 (n = 23) by one-sample Student’s t-tests. Inter-ocular differences were also assessed related to HLA-B27
presence and related to the status of current AU episode (initial or relapse).
Results: Subclinical MT is present in both quiet fellow-eyes and AU-affected eyes of patients. MT was found in
most cases of AU, even in phakic eyes with good VA. There was a larger increase in macular thickness in
HLA-B27-positive than in HLA-B27-negative patients. No differences in macular thickness were found between
patients with their first AU episode and patients with recurrent episodes.
Conclusions: MT probably reflects systemic immune-mediated response to the inflammatory disorder in AU, and it
is possible that HLA-B27-related factors are involved in the pathogenesis of AU. These observations are in line with
and extend the current understanding of the mechanisms behind MT in AU.Background
Anterior uveitis (AU) refers to a group of infectious and/
or immune- mediated inflammatory disorders primary
involving the iris and/or the anterior ciliary body of the
eye [1,2]. A common key sign of an active AU, along
with eye discomfort, is temporary reduced visual acuity
(VA), whereas it is the complications of an AU that may
lead to a long-lasting visual impairment.
Impairment of central vision due to persistent macular
edema is the most frequent complication of uveitis, the
occurrence rate of which differs for specific uveitis* Correspondence: wexler@ntnu.no
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reproduction in any medium, provided the orentities [3-5]. Although the rate of macular edema is
lowest in AU, it contributes greatly to the overall visual
impairment in the general population because of its high
prevalence [6,7].
Macular edema involves macular thickening (MT)
with or without cystoid space formation [8-10], which
may be detected and objectively quantified by the optical
coherence tomography (OCT) even in cases where MT
escapes clinical detection [11,12]. MT may occur in the
course of an AU even in eyes without posterior segment
disease, and it may or may not correspond to VA or the
grade of anterior chamber inflammation [11,13-15]. The
duration for MT after an AU episode has not been estab-
lished [16]. Although inter-eye asymmetry has been used
to demonstrate MT in uveitis-affected eyes [11,13], we
did not find any literature reporting macular thickness
values in fellow-eyes during an uveitis episode.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a high association with systemic rheumatic diseases
[17,18]. The prevalence of the HLA-B27 antigen, its
polymorphism and association strength with AU varies
in different populations, the latter probably due to a
combination of environmental and genetic factors [19-
22]. Higher rates of macular edema and more compli-
cated course have been reported in HLA-B27-related
AU [23,24], although results differ between studies. It is
feasible that not only macular edema but also MT is
associated with the HLA-B27 antigen. However, al-
though a possible association between moderate to se-
vere acute anterior uveitis and HLA-B27 was mentioned
in a previous letter [11], we found only one study com-
paring OCT in HLA-B27 positive vs. HLA-B27 negative
AU patients [13].
For these reasons we investigated a homogeneous
sample of phakic AU eyes with no clinically recognized
macular edema, and their fellow-eyes by OCT in order
to determine the frequency and extent of bilateral MT
in hospital-based patient population. Macular thickness
was also analysed with regard to the presence of HLA-
B27 and by recurrence status in order to improve our
understanding of the AU pathogenesis in our HLA-B27-
rich population [25,26]. Our data suggest that MT also is
present in quiet fellow-eyes of AU patients and that MT
is rather the rule than the exception, even in phakic
affected eyes with excellent visual acuity.
Methods
Adult (>18 years old) patients with AU classified
according to the primary anatomic site of the intraocular
inflammation [27] were prospectively recruited from De-
partment of Ophthalmology, St. Olavs University Hos-
pital. Initially 38 patients consented to participate in the
study. Their records were reviewed on inclusion and re-
reviewed at least 6 months later in order to ascertain
correct classification of the AU [2]. The study was
approved by the Regional Ethics Committee in May
2005. It was conducted in accordance with the Declar-
ation of Helsinki recommendations.
AU was defined as the presence of inflammatory cells
in the anterior chamber and corneal endothelium and
absence of posterior vitreous cells and/or other signs of
intraocular inflammation. Inclusion criteria were AU of
non-traumatic, non-infectious origin [28] without clinic-
ally recognized posterior segment involvement such as
vasculitis, macular edema or optic nerve involvement
seen on slit lamp biomicroscopy, best corrected VA
(Humphery automatic refractor HARK 597, Dublin, CA)
≥0.2 with spheric equivalent of ±6, and intraocular pres-
sure between 8 and 21 mmHg. Subjects with current or
previous ophthalmic history other than AU, significant
lens opacities, intraocular lens implants after cataract orrefractive surgery, glaucoma or diagnosed diabetes were
excluded.
Medical history regarding present and previous eye
symptoms, their laterality, duration and treatment was
recorded. For the purpose of this study time elapsed from
the diagnosis of an AU flare-up was used as an approxi-
mation of time elapsed from initial AU flare-up. Symp-
toms of coexistent spondyloarthropathy, morning muscle
stiffness and/or joint pain were asked for. The onset, dur-
ation and course of the AU and anterior chamber cells
grading was managed according to Standardization of
Uveitis Nomenclature [2]. Laboratory investigations were
tailored individually to rule out infectious/ systemic origin/
association of AU. HLA-B27 presence was assessed in all
patients, chest x-ray was performed in cases where oral
corticosteroids were instituted, sacroiliac spine x-ray was
performed if spondyloarthropathy was suspected, and
patients with considerable systemic complaints were seen
by a rheumatologist.
One patient was excluded due to amblyopic AU eye,
one due to previous uveitis-related cystoid macular
edema, one due to coexisting pigment dispersion syn-
drome, one due to abnormal pigmentation in macula of
the affected eye. Three eyes of two patients were
excluded due to lens implants, and another patient was
excluded due to presence of posterior vitreous cells dur-
ing the follow up period. Both eyes of two patients were
excluded due to lens opacities and low OCT signal
strength in the affected eye, leaving in total 59 included
eyes of 30 patients.
All patients were treated with dexamethasone 0.1% eye
drops and mydriatics according to the severity of their
AU [29]. Eight subjects received a short course of oral
prednisolone in addition to eye drops, because the AU
did not respond promptly or adequately to initial topical
treatment. Treatment was tapered down slowly after all
clinical signs of AU had gone into remission. Three
patients were using immunomodulatory agents which
had been instituted before the actual AU episode.
All patients but one (who was Asian) were white. One
patient had undergone LASIK surgery in both eyes more
then 2 years prior to initial AU episode.
Data from healthy subjects reported by us earlier [30]
were used as controls. Their HLA-B27 status is not
known. Controls were age and gender matched to
patients: mean age in female patients (n = 15, 50%
females in sample) was 40.7 (SD 12.8) range 19–56. Fe-
male controls ≤53 years were included, their mean age
was 40.5 (SD 9.7) range 21–53 (n = 47, 51% females in
sample). Mean age in male patients (n = 15) was 40.3
(SD 13.0) range 21–69 and in male controls (n = 45, 49%
males in sample) was 39.0 (SD 12.0) range 22–63. Con-
trols were further gender-and age matched according to
patient subgroups.
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Zeiss Meditec, Inc., Dublin, CA) scans in macular thick-
ness protocol (software v.5.0.1) were obtained by a single
operator on inclusion and on follow up. Follow up inter-
vals were individually tailored depending on the severity
of AU, type of treatment and treatment response, as well
as practicability for ophthalmologist and patient. Scans
with signal strength ≥3 qualified for inclusion. Scans
were qualitatively evaluated as to the presence of epiret-
inal membrane, vitreomacular traction, cystoid space
formation and serous macular detachment. Only one
scan was excluded due to cystoid space formation. Mean
macular thickness was used in subsequent analyses.
The macula was divided into 9 areas as described in our
previous paper [30]: Mean foveal thickness (MFT=F1)
from a central macular area of one millimeter in diameter,
the inner ring (F2-F5) and the outer ring (F6-F9), each
divided into four quadrants. The outer ring diameters
measured 2.22 and 3.45 millimeters respectively. Regional
variables MCT (mean central thickness) and MPT (mean
peripheral thickness) were defined by averaging middle
(MCT= (F2+ F3+F4+F5)/4) and outer (MPT= (F6+F7+
F8+ F9)/4) ring data (Figure 1). Averaged mean total
macular thickness (MTT) was calculated by averaging the
nine macular areas (F1 + F2+ F3+F4+F5+F6+ F7+F8+
F9)/9. The inner region (MFT=F1) and mean minimal
foveolar thickness (MMFT=F0) were also analyzed.
In total 126 scans from both eyes in 29 patients, sev-
eral of which were repeatedly taken on follow-up were
available. Inter-ocular differences between AU-affected
and their fellow- eyes were analyzed in relation to time
elapsed from AU flare-up.
Cases were grouped in two by time elapsed from flare-
up. Early measurement was defined by ≤2 weeks, late
measurement by 7–12 weeks follow-up. Scans taken at 3–
6 weeks and at long time remission were not included
(favoring polarization). In cases where several observa-
tions of same subject were available in each group (early








Figure 1 Macular areas on the Stratus OCT scan.chosen. Finally bilateral scans from 21 patients measured
early and 8 patients measured late were available. Post-
hoc two-sample test was performed on inter-ocular differ-
ences in macular thickness by the Mann–Whitney U-test.
For further inclusion in statistical analysis only one bi-
lateral scan from each patient was chosen from 126
scans. In cases where several scans of a same patient
were available, the scan taken 1–2 weeks after flare-up
was preferred. Finally 59 scans (29 bilateral and one uni-
lateral) from 15 males and 15 females were analyzed.
Normal MTT ranges were defined by MTT ±2SD,
stratified by gender in controls; (238.35 μm - 259.33 μm)
in females and (243.95 μm - 271.81 μm) in males.
Macular thickness in AU eyes of 30 patients were
compared with macular thickness in gender- and age
matched controls (n = 92) (one eye of each subject in
both groups) by two-sample Student’s t-test. Inter-ocular
differences in macular thickness between affected and
fellow-eyes (n = 28) were assessed in all patients and in a
subgroup with best corrected visual acuity ≥0.8 (n = 23),
by one-sample Student’s t-tests (expected value = 0).
Macular thickness in currently quiet fellow-eyes
(n = 28) (defined by no symptoms of AU for at least
3 months prior to assessment) and in a subgroup of
fellow-eyes with no previous uveitis (n = 16) in patients
was compared with macular thickness in correspond-
ingly gender- and age matched controls (n = 85, n = 77)
by two-sample Student’s t-test.
Inter-ocular differences in macular thickness between
AU and their fellow-eyes were compared by HLA-B27
(positive n = 17 versus negative n = 8). Inter-ocular differ-
ences were also compared between the initial AU epi-
sode (n = 15) and subsequent episodes (n = 9). Both
analyses were carried out in scans taken at ≤ 6 weeks
from flare-up. A non-parametric test for two independ-
ent samples (Mann–Whitney U-test) was used.
SPSS v.17.0 was used for statistical analysis. All tests
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Patient demographics and their clinical history and
investigations are described in Table 1.
The change in inter-ocular differences in mean macu-
lar thickness between affected and fellow-eyes as a func-
tion of time elapsed from an AU flare-up in 63 bilateral
OCT scans of 29 patients is demonstrated in Figure 2
(one non-repeated scan in 9 patients, 2 repeated scans
in 11 patients, 3 repeated scans in 5 patients, 4 repeated
scans in 3 patients and 5 repeated scans in one patient).
Patients measured late had larger inter-ocular differ-
ences in macular thickness: mean differences for MMFT
(18.8 μm p=0.057), MFT (19.4 μm p=0.068), MCT
(13.4 μm p=0.040), and MPT (9.7 μm p=0.081).
Macular thickening was observed in 70% of all 30 AU
patients; in 79% of patients with acute AU and in 55% of
patients with recurrent or chronic AU (Table 1). Macu-
lae in patients were significantly thicker in all regions of
AU eyes (p< 0.0005; Table 2).
Maculae were also thicker in most regions of quiet
fellow- eyes compared with gender-and age matched
controls (Table 3). Thicker foveola and a trend towards
thicker fovea were also observed in a subgroup of
patients with no previous uveitis in fellow- eyes
(Table 3).
Maculae in AU eyes were thicker than in their fellow-
eyes, also in a subgroup of patients with excellent visual
acuity (≥0.8) (Table 4).
The majority of our patients were HLA-B27-positive
(70%), they had acute AU (63%) which was of limited
duration (77%). Most patients had mild anterior cham-
ber inflammation (grade ≤1+) (73%) and excellent VA
(≥0.8) (80%) when scans were taken (Table 1). Inter-
ocular differences in macular thickness were larger in
HLAB-27-positive than in HLAB-27-negative patients
(on scans taken at ≤6 weeks from AU flare-up); MMFT:
p = 0.43 MFT: p = 0.083 MCT: p = 0.032 MPT: p = 0.025
MTT: p = 0.011 (exact two-sided p-values). Mean inter-
ocular differences are shown in Figure 3.
Inter-ocular differences were compared between
patients in which the current AU was their initial epi-
sode (n = 15) with those in which the episode was subse-
quent (n = 9) (on scans taken at ≤6 weeks from AU flare-
up). Differences were small and did not achieve the set
statistical significance; MMFT: p = 0.27, MFT: p = 0.44,
MCT: p = 0.83, MPT: p = 0.69, MMT: p = 0.77) (exact
two-sided p-values).
Discussion
In the present study we report a new observation: macu-
lar thickening is present in quiet fellow-eyes of AU
patients, also in the foveola of fellow-eyes with no previ-
ous uveitis. This finding suggests that an AU episode is
accompanied by a systemic immune-mediated responsewhich affects both patients’ eyes. Another important
finding in the present study was that MT is rather the
rule than the exception even in phakic AU eyes with
good VA, suggesting that some extent of relative MT ac-
companies most, even uncomplicated AU cases. In
addition, MT seems to be larger in HLA-B27-related
than in HLA-B27-negative AU, suggesting a stronger
subclinical involvement of the posterior segment in
HLA-B27-positive patients, which is probably not
related to recurrence. These observations are in line with
and extend the current understanding of the mechan-
isms behind MT in AU. It is assumed that they are simi-
lar to those involved in uveitic macular edema. It is
thought that trans-cellular mechanisms along with a
functioning blood-retina barrier regulate the fluid equi-
librium in the retina [31]. Biologically active substances
related to inflammation together with other predisposing
factors may compromise the functional integrity of this
barrier with a consequential MT in uveitis [32,33].
MT has been previously described in eyes with chronic
or severe AU [11,34] and in AU with a broader range of
inflammation severity [13]. The latter study reported an
overall rate of MT in 42% of AU patients, although eyes
with pseudophakia and cystoid macular edema were
included. Since cataract surgery and cystoid space for-
mation may contribute to MT [10,35,36], we expected to
find lower rates of MT in our sample, from which eyes
with psedophakia and detectable cystoid space formation
were excluded. In addition our definition of MT was
strict and gender- adjusted. Nonetheless MT was
observed in 70% of AU eyes in our sample. Our data
suggest that MT is rather the rule than the exception
even in phakic eyes with excellent VA.
Besides the possible genuine differences in the rate
and degree of MT between Castellano et al..’s [13] and
our samples, the measured differences may also be
attributed to dissimilar time intervals between the AU
flare-up and OCT examination. Castellano et al. [13]
included only OCT scans taken on first visit, although
56% of their patients had chronic AU. Our data may in-
dicate that MT lags several weeks behind the clinical AU
flare-up, which is coherent with Traill et al.’s assumption
[11]. Hegde et al. [37] observed no MT in patients with
acute AU of ≤ 1 week duration, and it seems that MT
peaks at about 6–12 weeks after the initial flare-up,
often after a clinical resolution of the AU.
For these reasons we assume that macular thickness
increases with time elapsed from the initial flare-up, al-
though the statistical evidence for this assumption is ra-
ther weak. Individual clinically tailored follow-up
intervals were not optimal for the statistical analyses,
which eventually resulted in a small study sample for the
“late” follow-up group. However, Peizeng et al. [38]
detected inflammatory changes in the ciliary body on
Table 1 Patients with anterior uveitis (AU; n = 30): Clinical history and investigations
Female Male Total
Age Mean age (range): 40.7 (19–56) 40.3 (21–69)
Duration Limited≤ 3 months 9 14 23
Persistent> 3 months 6 1 7
Course Acute (sudden onset and limited duration) 9 10 19
Recurrent (repeated episodes separated by periods of
inactivity without treatment ≥3 months in duration)
0 5 5
Chronic (persistent uveitis with relapse in <3 months after
discontinuing treatment)
6 0 6
Treatment duration <1 week 2 0 2
1-2 weeks 7 12 19
3-6 weeks 2 2 4
7-12 weeks 0 1 1
Chronic (>12 weeks) 3 0 3
Long term remission 1 0 1
HLA-B27 Negative 8 1 9
Positive 7 14 21
Relative macular thickening Normal (235-259 μm females, 244-272 μm males) 5 3 8
Thickening (≥259 μm females, ≥272 μm males) 9 12 21
Atrophy (≤238 μm in females, ≤243 μm males) 1 0 1
Best corrected visual acuity ≥0.8 11 13 24
0.6-0.7 4 0 4
0.4-0.5 0 1 1
0.2-0.3 0 1 1
AU episode First episode 7 8 15
Several episodes 5 7 12
Chronic 3 0 3
Anterior chamber cells Grade 0, <1 cell 4 3 7
Grade 0.5+, 1–5 cells 1 2 3
Grade 1+, 6–15 cells 7 5 12
Grade 2+, 16–25 cells 3 4 7
Grade 3+, 26–50 cells 0 1 1
Spillover No retrolental cells 13 9 22
1-5 retrolental cells 2 6 8
Systemic symptoms Diagnosed spondyloarthropathy 2 9 11
Joint/ skin/ intestinal/urogenital complaints 4 3 7
Tiredness, morning stiffness/ pain 6 2 8
None 3 1 4
Systemic treatment None 11 8 19 (11)*
Oral prednisolone 2 6 8 (8)*
Immunomodulatory treatment 2 1 3 (2)*
Uveitis in contralateral eye Never uveitis in contralateral eye 6 10 16 (12)*
At least one earlier episode 7 5 12 (9)*
Bilateral uveitis now 2 0 2 (0)*
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Table 1 Patients with anterior uveitis (AU; n = 30): Clinical history and investigations (Continued)
Contralateral AU last three month Never uveitis 6 10 16
≤ 3 months prior to examination 1 4 5
≥ 3 months prior to examination 8 1 9
* The number of HLA-B27+ patients are given in parentheses.
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absence of inflammatory anterior chamber cells. It is ac-
cordingly possible that a continuous release of inflam-
matory mediators from the ciliary body can explain the
time lag.
We observed that differences in macular thickness be-
tween affected eyes and fellow-eyes of patients were
smaller than differences between patient’s affected eyes
and controls. This observation can be explained if the
increase in macular thickness after a previous AU epi-
sode lasts for at least 3 months (n = 12). However, the
duration of residual MT after an AU episode has not
been established. Traill et al. found MT in 45% of eyes
at 6 months [11] while Moreno-Arrones et al. found no
MT at 6.3 months [16]. Bilateral AU (n = 1 in our sam-
ple) will decrease the inter-eye MT difference.
Subclinical AU in some fellow-eyes should also be
considered. Indeed central maculae in fellow-eyes with
no previously diagnosed uveitis (n = 16) were thicker
than in controls. We did not find any literature dealing
with macular thickness in unaffected fellow-eyes during
an uveitis episode. We do not know the reason for this
observation. However activation of the peripheral immu-
noregulatory mechanisms and increased levels of ocular
autoantigens have been found in AU patients [39,40].
Furthermore, up-regulated levels of IL-22 which may
compromise the blood-retina barrier and allow biologic-
ally active substances and water to enter the retina were
found in peripheral blood in uveitis [41,42]. We
hypothesize that similar mechanisms may also influence





















Figure 2 Mean inter-ocular differences in macular thickness (micron)
dMMFT: mean minimal foveolar thickness, dMFT: mean foveal thickness, dMincrease in MT in both eyes of patients even when AU
is unilateral.
Posterior segment involvement in HLA-B27-related
uveitis is not uncommon, and it is probably under-
recognized [43-45]. Power et al. [23] reported that
cystoid macula edema was five times more frequent in
HLA-B27-positive than HLA-B27-negative AU, the oc-
currence of which may predict a less favorable visual
outcome [46]. However, Castellano et al. [13] found no
differences in MT by HLA-B27 on patients’ first visit.
We observed a larger MT in HLA-B27-related than in
HLA-B27-negative AU. It is possible that early MT is in-
dependent of the antigen, while the magnitude of further
increase is related to both the HLA-B27 and/or its poly-
morphism, along with the time perspective discussed
above. It is accordingly possible that HLA-B27-related
AU is accompanied by a larger or a more prolonged MT
than HLA-B27-negative AU.
We wonder whether the above described dispute
about the duration of residual MT after an AU episode
[11,13,16] is partly related to different HLA-B27- antigen
distribution in studied samples; Traill et al.’s sample was
dominated by HLA-B27-positive patients (as the case is
with our sample, while only 42% of Castellano et al.’s
sample are HLA-B27-positive. Moreno-Arronez et al. do
not mention the distribution of HLA-B27 antigen in
their sample.
The absence of cystoid spaces and detectable epiretinal
membrane is consistent with good VA [8,10] which
probably carries a beneficial long-term visual prognosis
for patients in our sample. Markomichelakis et al. [8]Long-term 
remission (n=9)










related to time elapsed from anterior uveitis (AU) flare-up.
CT: mean central thickness, dMPT: mean peripheral thickness.
Table 2 Macular thickness(SD) (micron) in AU-affected eyes of patients and controls
Macular regions/OCT SS Patients (n =30) Controls (n = 92) Mean differences(SD) p-value1
F0 (MMFT) 205(34) 177(20) 28(7) <0.0005
Inner ring F1(MFT) 237(27) 212(16) 24(5) <0.0005
Middle ring (MCT) 295(21) 273(15) 22(4) <0.0005
Outer ring (MPT) 296(20) 274(15) 21(3) <0.0005
Total region (MTT) 276(21) 253(13) 23(4) <0.0005
OCT SS 6.2(2) 6.1(2) 0.07 0.85
AU: anterior uveitis, OCT: Optical coherence tomography, SS: signal strength. Five macular areas: MMFT: mean minimal foveal thickness, MFT: mean foveal
thickness, MCT: mean central thickness, MPT: mean peripheral thickness, MTT: mean total thickness. The outer diameter of the inner, middle and outer rings is 1,
2.22 and 3.45 millimeters respectively. For further definition of macular regions see Figure 1. 1Two-sample Student's t-test (affected eyes of patients vs. gender-
and age matched controls).
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47% of eyes by 12 months follow-up with medical treat-
ment. They suggested that diffuse MT could carry a
negative prognostic significance because it was not trea-
ted due to good VA. However, diffuse MT may adversely
affect visual function on persistence or during inflamma-
tory relapse [47]. We did not observe differences in MT
on recurrence. However, other aspects of visual function
such as central visual field impairment may occur even
on complete resolution of edema despite good VA
[48,49]. The prognostic relevance of MT on long-term
visual function in AU is not yet known.Table 3 Macular thickness(SD) (micron) in quiet
fellow- eyes of AU patients and controls
Macular regions/ OCT SS Patients Controls p-value1
Currently quiet eyes
(contralateral to the AU eye)
(n = 28)2 (n = 85)
F0 (MMFT) 195(27) 179(20) 0.006
Inner ring F1 (MFT) 224(21) 214(15) 0.028
Middle ring MCT 281(17) 274(14) 0.022
Outer ring MPT 281(17) 274(15) 0.057
Total region MTT 262(16) 254(13) 0.024
OCT SS 6.2(2) 6.2(2) 0.76
Quiet eyes with no
previously recognized AU
(n = 16) (n = 77)
F0 (MMFT) 193(22) 179(20) 0.016
Inner ring F1 (MFT) 223(19) 215(15) 0.092
Middle ring MCT 279(15) 275(14) 0.23
Outer ring MPT 279(16) 275(14) 0.38
Total region MTT 260(15) 255(12) 0.14
OCT SS 5.9(2) 6.1(2) 0.58
AU: anterior uveitis, OCT: Optical coherence tomography, SS: signal strength.
Five macular areas: MMFT: mean minimal foveolar thickness, MFT: mean foveal
thickness, MCT: mean central thickness, MPT: mean peripheral thickness, MTT:
mean total thickness. The outer diameter of the inner, middle and outer rings
is 1, 2.22 and 3.45 millimeters respectively. For further definition of macular
regions see Figure 1. 1Two- sample Student's t-test (patients vs. gender-and
age matched controls). 228 patients with bilateral scans and unilateral uveitis
were included in this analysis.The present study has some limitations. Although hos-
pital records were examined in all cases, the previous
history depended on patients’ recollection ability in
some cases.
Follow-up intervals were individually tailored depend-
ing on the AU severity, treatment intensity and response,
as well as practicability for ophthalmologist and patient.
Intervals were therefore not standardized for the pur-
pose of statistical analyses. In order to demonstrate an
increase in thickness as a function of time elapsed from
AU flare-up, mean inter-ocular differences were aver-
aged from different cases at different intervals in lack of
sufficient repeated longitudinal data. Longer follow-upTable 4 Mean differences in macular thickness(SD)
(micron) between patients’ affected and fellow- eyes




All patients (n = 28)2
F0 (MMFT) 11.6(21) 2.91(27) 0.007
Inner ring F1 (MFT) 14.1(16) 4.71(27) <0.0005
Middle ring MCT 14.8(12) 6.42(27) <0.0005
Outer ring MPT 15.0(12) 6.83(27) <0.0005
Total region MTT 14.7(12) 6.31(27) <0.0005
OCT SS −0.04(2) −0.09(27) 0.93
Patients with VA≥ 0.8 (n = 23)
F0 (MMFT) 11.6(22) 2.54(22) 0.019
Inner ring F1 (MFT) 14.6(16) 4.42(22) <0.0005
Middle ring MCT 15.5(12) 6.27(22) <0.0005
Outer ring MPT 15.6(11) 6.86(22) <0.0005
Total region MTT 15.3(12) 6.20(22) <0.0005
OCT SS −0.22(2) −0.49(22) 0.63
OCT: Optical coherence tomography, SS: signal strength, MMFT: mean minimal
foveolar thickness, MFT: mean foveal thickness, MCT: mean central thickness,
MPT: mean peripheral thickness, MTT: mean total thickness. The outer
diameter of the inner, middle and outer rings is 1, 2.22 and 3.45 millimeters
respectively. For further definition of macular regions see Figure 1. VA: visual
acuity. 1One-sample Student's t-test (test value = 0 for differences between


































































Figure 3 Mean inter-ocular differences (and 95% confidence intervals) (micron) by HLA-B27 in anterior uveitis. dMMFT: mean minimal
foveolar thickness, dMFT: mean foveal thickness, dMCT: mean central thickness, dMPT: mean peripheral thickness.
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http://www.biomedcentral.com/1471-2415/12/30intervals could preferentially select the more severe or
longer-lasting cases, biasing the time frame towards lar-
ger measured thickness (if MT is related to severity and/
or chronicity, which we do not know) in our small study
sample. However, according to medical records this is
not the case. Nevertheless, these data should be inter-
preted with care until confirmed in larger samples.
Three patients had been receiving an immunomodula-
tory agent for rheumatic disease other than uveitis be-
fore current AU flare-up. Eight patients received a short
course of oral prednisolone during current AU episode.
Prednisolone alone or in combination with other immu-
nomodulatory agents is the mainstay treatment in uveitis
and uveitic edema [32,33,50,51]. Immunomodulatory
agents may even reduce frequency of recurrence [52,53].
Thus systemic treatment these 11 patients received may
have protected their retinae from further thickening.
Macular thickness may have otherwise reached even
greater values than observed in this study.Conclusions
Subclinical MT is present in both affected eyes and quiet
fellow-eyes of AU-patients. MT is detected by OCT dur-
ing most cases of AU, even in phakic eyes with good VA
and in quiet fellow-eyes with no previous uveitis. MT
probably reflects systemic immune-mediated response to
the inflammatory disorder in AU, and it is possible that
HLA-B27-related factors are involved in the pathogen-
esis of AU. These observations are in line with andextend the current understanding of the mechanisms be-
hind MT in AU.
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